Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase

Anaplastic lymphoma kinase (ALK) is validated as a therapeutic molecular target in multiple malignancies, such as non-small cell lung cancer (NSCLC). However, the feasibility of targeted therapies exerted by ALK inhibitors is inevitably hindered owing to drug resistance. The emergence of clinically...

Full description

Bibliographic Details
Main Authors: Shuai Liang, Qing Wang, Xuesen Qi, Yudi Liu, Guozhen Li, Shaoyong Lu, Linkai Mou, Xiangyu Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
anaplastic lymphoma kinase
non-small cell lung cancer
targeted therapy
drug resistance
molecular dynamics simulations
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.808864/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.808864/full

Similar Items